Please assess the completion status of the following clinical trial:

Trial Title: Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Microbiologically confirmed clinical diagnosis of interdigital tinea pedis~* If female and of child bearing potential, prepare to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g., condom, intra-uterine device (IUD), oral, transdermal, injected or implanted hormonal contraceptives).~* A confirmed clinical diagnosis of interdigital tinea pedis. Lesions are to be predominately interdigital but may extend to other areas of the foot (the non-interdigital lesions must not be hyperkeratotic).~* The presence of tinea pedis infection, confirmed by the observation of segmented fungal hyphae during a microscopic potassium hydroxide (KOH) wet mount examination (potassium hydroxide mount preparation).~* Identification of an appropriate dermatophyte by culture sent to the central laboratory. The appropriate dermatophytes are Trichophyton rubrum, Trichophyton mentagrophyte or Epidermophyton floccosum.~Exclusion Criteria:~* Use of any of the following within the indicated timeline:~* Oral or injectable steroids~* Any oral anti-fungals within 4 weeks of the study start~* Use of topical corticosteroids or any other topical antipruritics on the feet within 72 hours of the study start.~* Any prescription or over-the-counter (OTC) topical antifungals on the feet within two weeks prior to study entry~* Use of any antihistamines within 72 hours of the study start.~* Any known hypersensitivity to butenafine or other antifungal agents.~* Evidence of any concurrent dermatophytic infection of toe nails (onychomycosis) or other dermatological condition of the foot that may interfere with the Investigator's evaluation of tinea pedis.~* Patients with recurrent tinea pedis (more than 3 infections in the past 12 months) who have been unresponsive to previous antifungal therapy.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Butenafine cream 1% (Taro) (Type: EXPERIMENTAL): Butenafine cream manufactured by Taro applied for 7 days
- Lotrimin Ultra (butenafine) 1% (Type: ACTIVE_COMPARATOR): Lotrimin Ultra (butenafine) applied for 7 days
- Vehicle (Type: PLACEBO_COMPARATOR): Butenafine vehicle applied for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).